Related Experiment Videos
Improved phagocyte response by co-amoxiclav in renal transplant recipients
A M Cuffini1, V Tullio, F Giacchino
1Department of Public Health and Microbiology, University of Turin, Italy.
Background:
Infectious diseases are a major source of morbidity and mortality for immunosuppressed transplant recipients and the antimicrobial chemotherapy can be often less effective in these individuals, because the contribution of underlying host defenses is absent.
Methods:
The influence of co-amoxiclav on the functions of polymorphonuclear granulocytes (PMNs) from renal transplant recipients were investigated.
Results:
PMNs from renal transplant recipients showed a diminished phagocytic activity with reduced phagocytosis and bactericidal activity against intracellular Klebsiella pneumoniae, compared to that seen with PMNs from healthy subjects. Co-amoxiclav significantly elicited the functions of PMNs from uremic patients, resulting in an increased percentage of ingested klebsiellae and in a higher bactericidal effect (98-99%), compared with the drug-free control system. When PMNs were collected from renal transplant recipients treated with co-amoxiclav a significant high increase in both phagocytosis and killing activity were detected, showing the co-amoxiclav capability of "restoring" even in vivo the depressed primary functions of PMNs.
Conclusions:
The interesting beneficial properties of co-amoxiclav, which result in restoring the phagocyte-dependent response in renal transplant patients both in vitro and in vivo, may make this drug more suitable for the treatment of infections in patients with defects of phagocyte functions.
Insights
Co-amoxiclav enhances polymorphonuclear granulocyte (PMN) function in renal transplant recipients. This study shows co-amoxiclav restores phagocytic and bactericidal activity in PMNs, improving infection defense.
Area of Science:
- Immunology
- Pharmacology
- Transplantation
Background:
- Infectious diseases pose significant risks for immunosuppressed transplant recipients.
- Antimicrobial chemotherapy efficacy is often limited by compromised host defenses in these patients.
Purpose of the Study:
- To investigate the impact of co-amoxiclav on polymorphonuclear granulocyte (PMN) functions in renal transplant recipients.
- To assess co-amoxiclav's ability to restore depressed PMN functions in vivo and in vitro.
Main Methods:
- Assessed phagocytic and bactericidal activity of PMNs from renal transplant recipients against Klebsiella pneumoniae.
- Compared PMN function in patients treated with co-amoxiclav versus a drug-free control.
Main Results:
- PMNs from renal transplant recipients exhibited diminished phagocytic and bactericidal activity compared to healthy individuals.
- Co-amoxiclav significantly enhanced PMN phagocytosis and bactericidal activity (98-99%) in uremic patients.
- In vivo administration of co-amoxiclav restored phagocytosis and killing activity in renal transplant recipients' PMNs.
Conclusions:
- Co-amoxiclav demonstrates beneficial properties in restoring phagocyte-dependent responses in renal transplant patients.
- The drug's ability to restore PMN function in vitro and in vivo suggests suitability for treating infections in patients with phagocyte defects.